2000
The parent company of Hybribio, Hong Kong Science & Technology Ltd., established
2002
Co-established Hong Kong Gene Technology Ltd. with the University of Hong Kong, acquired two US patents
– Flow-through Hybridization Technology
2003
Established Chaozhou Hybribio Biological Instrument Ltd. (former name of the company)
2004
Established Chaozhou Hybribio Biochemistry Ltd.
2008
The 1st Hybribio’s HPV Seminar held
2009-2010
Jointly organized with the Ministry of Health and the Chinese Physician Association to conduct trainings for 600 national base-level doctors for 3 years
Assisted Chaozhou government with the cervical cancer screening for 300,000 women in the rural area
Awarded the Social Responsibility Award by the Chinese Physician Association
2011
The Launching Ceremony of China HPV Database System and The 2nd Hybribio’s HPV Seminar held
2012
Guangdong HPV Related Molecular Diagnosis Engineering Technology R&D Center established
Key Program of the 12th Five-Year Plan for the Development of Biomedical Industry in Guangdong Province
HPV health checkup for 120,000 female employees in Daqing Petroleum
2013
Hong Kong Molecular Pathology Diagnostic Centre Ltd. established
The postdoctoral research station established
Key enterprise of strategic emerging industries in Guangdong Province
2014
Hybribio Enterprise Technology Center was named Guangdong Provincial Enterprise Technology Center
HPV cervical cancer screening for 150,000 female civil servants in Hunan Province
2015-2016
Hybribio medical laboratories established nationwide
Guangdong Hybribio Biochip R & D Industrial Base officially established, as a national project for the development of strategic emerging industry
HPV diagnostic kits and the gene chip preparation (ZL200710030723.6) method won the Golden Award of the 2016 Chinese Patent Award
2017
Hybribio (stock code: 300639) was successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market.
2018-2019
Top 50 Biotechnology Innovation Enterprises in the Guangdong, Hong Kong and Macau Greater Bay Area
Hybribio School of Life and Health officially established
Establishment of a workstation for overseas intelligence serving the Country
Formal strategic cooperation with European Molecular Genetic Quality Network (EMQN)
2020
Two COVID-19 diagnostic kits (RT-PCR method and Sanger Sequencing method) developed
Hybribio Medical Laboratories carried out COVID-19 detection all around the country
The first diagnostic kit for detection of 10 reproductive tract infection pathogens simultaneously was approved for selling
2021
Fully devoted to fight against COVID-19 pandemic at home and abroad
2022
Construction commencement of Hybribio Medical Science Park
Monkeypox Virus Real-time PCR Kit, SOX1 and PAX1 Methylation Real-time PCR Kit obtained CE certificate
2023
As of Dec 2023, Hybribio has provided over 1 billion COVID-19 RT-PCR tests in China
Obtained the 1st NMPA approval for cervical cancer primary screening
Pharmacogenetics – ApoE and SLCO1B1 Gene MCA Real-time PCR Kit, MTHFR Gene MCA Real-time PCR Kit obtained NMPA approval
2024
Pharmacogenetics – CYP2C9 and VKORC1 Gene MCA Real-time PCR Kit obtained NMPA approval